Daily Archives: April 10, 2017

Cellular Biomedicine Group (CBMG) and GE Healthcare Life Sciences China Announce Strategic Partnership to Establish Joint Technology Laboratory to Develop Control Processes for the Manufacture of CAR-T and Stem Cell Therapies

SHANGHAI, China and CUPERTINO, Calif., April 10, 2017 (GLOBE NEWSWIRE) — Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (CBMG or the Company), a leading clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases and GE Healthcare Life Sciences China, today announced that they have established a strategic research collaboration to co-develop certain high-quality industrial control processes in Chimeric Antigen Receptor T-cell (CAR-T) and stem cell manufacturing.  In connection with the collaboration, a joint laboratory within CBMG’s new Shanghai Zhangjiang GMP-facility will be established and dedicated to the joint research and development of a functionally integrated and automated immunotherapy cell preparation system.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/ab5bc905-b526-4e86-98bd-c96e306b5796

CBMG and GE Healthcare Life Sciences China plan to develop state-of-the-art automated CAR-T and stem cell manufacturing capabilities that build upon the accreditation of CBMG’s GMP facilities in Shanghai, Wuxi and Beijing.  The co-development activity will aim to standardize the delivery of cell manufacturing to potentially improve throughput, alleviate cost burdens and to minimize variability in cell production, which may increase the availability of engineered cells upon commercialization.

This partnership combines CBMG’s scientific expertise in the manufacturing of CAR-T and stem cell production in China and GE Healthcare’s renowned expertise in the design and development of innovative manufacturing technologies for the biopharmaceutical industry.

Recently, CBMG announced that its new Zhangjiang facility, together with an expanded Wuxi, and Beijing GMP-facilities, will have a combined 70,000 square feet for development and production. This will enable CBMG to conduct simultaneous clinical trials for multiple CAR-T and stem cell product candidates. At full production volumes, these facilities could support the treatment of up to 10,000 cancer patients and 10,000 knee osteoarthritis patients per year.

“GE Healthcare‘s selection of our facility to serve as their showcase site in China, credits our GMP stature and capabilities. Our team of scientists has spent years refining our manufacturing process to become one of the very few cell therapy companies with fully in-house integrated chemistry, manufacturing, and controls (CMC) processes for clinical grade CAR-T cells, plasmid and viral vectors bank production. We understand that one of the impending barriers to adoption of immuno-oncology and stem cell therapies is the logistics in manufacturing and we look to take an expanded role both domestically and potentially globally.  We are pleased to be in a strategic partnership with GE Healthcare and look forward to showcasing our facilities and the mutual benefit this joint laboratory will bring,” commented Tony Liu, Chief Executive Officer, CBMG.

“Cell therapy as an industry continues to refine and evolve in China with vast potential to change the ways various diseases are treated.  GE continues investing in technologies and services aimed at the thriving cell therapy industry with a firm commitment of making these promising therapies accessible through successful industrialization. We are pleased to partner with CBMG, a leader in CAR-T and stem cell development in China and to take advantage of their excellent CMC cell production capabilities. Collaboration with ambitious partners like CBMG who share our vision is necessary for advancing innovation and delivering comprehensive manufacturing solutions for cell and regenerative medicines,” said Li Qing, General Manager, GE Healthcare Life Sciences, Greater China.

About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) develops proprietary cell therapies for the treatment of cancer and degenerative diseases. We conduct immuno-oncology and stem cell clinical trials in China using products from our integrated GMP laboratory. Our GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards.  CBMG recently commenced two Phase I human clinical trials in China using CAR-T to treat relapsed/refractory CD19+ B-cell Acute Lymphoblastic Leukemia (ALL) and Refractory Diffuse Large B-cell Lymphoma (DLBCL) as well as an ongoing Phase I trial in China for AlloJoinTM (CBMG’s “Off-the-Shelf” Allogeneic Human Adipose-derived Mesenchymal Stem Cell) for the treatment of Knee Osteoarthritis (KOA). CBMG was also recently awarded $2.29 million from the California Institute for Regenerative Medicine (CIRM) to support pre-clinical studies of AlloJoinTM for Knee Osteoarthritis in the United States. To learn more about CBMG, please visit www.cellbiomedgroup.com.

About GE Healthcare
GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world.  GE (NYSE:GE) works on things that matter – great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients. For more information about GE Healthcare, visit our website at www.gehealthcare.com.

Forward-Looking Statements
This press release contains forward-looking statements—including descriptions of plans, strategies, trends, specific activities, investments and other non-historical facts—as defined by the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently uncertain, and actual results could differ materially from those anticipated due to a number of factors, which include risks inherent in doing business, trends affecting the global economy (including the devaluation of the RMB by China in August 2015), and other risks detailed in CBMG’s reports filed with the Securities and Exchange Commission, quarterly reports on form 10-Q, current reports on form 8-K and annual reports on form 10-K. Forward-looking statements may be identified by terms such as “may,” “will,” “expects,” “plans,” “intends,” “estimates,” “potential,” “continue” or similar terms or their negations. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.

The photo is also available at Newscom, www.newscom.com, and via AP PhotoExpress.

Contacts:
Sarah Kelly
Director of Corporate Communications, CBMG
+1 408-973-7884
sarah.kelly@cellbiomedgroup.com

Vivian Chen
Managing Director Investor Relations, Citigate Dewe Rogerson
+1 347 481-3711
vivian.chen@citigatedr.com

Min is still in critical condition at Rajavithi hospital

25-year-old Rapeeporn "Min" Nasa-an remains in critical condition and needs close monitoring at Rajavithi hospital, the team of doctors said yesterday.

Min returned in coma condition on Saturday from South Korea aboard a Thai Airways International's flight and sent to Rajavithi hospital.

Doctors said she remains in critical condition as the result of oxygen depletion for a long period.

Although she regained consciousness, she still could not speak and needs breathing aids, they said.

Dr Thirapol Tophantananond, director-general of the Medical Department, said her brain was damaged due to oxygen depletion and the chance to return to normal condition was not known, depending on how much the brain was damaged.

He said what the team of doctors was trying its best was to keep her brain from further damage from seizure disorder.

Meanwhile her parents yesterday also denied that their daughter overdrinking alcohol before falling unconscious.

They also assured donors that all the money donated for their daughter would be spent on medical expenses at the utmost interest but declined to say how much the donation now is so far.

Source: Thai Public Broadcasting Service (Thai PBS)

Water splashing banned from 5 roads around world heritage sites

Five roads around the world heritage sites in Ayutthaya province will be banned from Songkran water splashing activities during April 13-15.

The roads are Rojana from Grand market intersection to Srisanphen road; Ayutthaya-Ang Thong road from Luangpor Chao Noi U-turn to U-thong road intersecton; Ayutthaya-Sena road from Wat Tha Karong intersection to U-thong road intersection; Klong Sabua road Wat Na Phra Meru intersection; Hua Ror road from slaughter house intersection to U-thong intersection.

Trucks carrying water containers or revelers on their way to engage in water flashing activities will be banned from the roads from 9 am to 5 pm during the three-day period.

Ayutthaya provincial administration expects a large number of both Thai and foreign tourists visiting the world heritage sites during the Songkran festival.

Source: Thai Public Broadcasting Service (Thai PBS)

Nationwide crime crackdown before Songkran

About 5,000 criminal and drug suspects have been rounded up by police of First Region Provincial Police Bureau since March 31 as part of the police's nationwide crime crackdown ahead of the Songkran festival.

Police also seized 100 illegal firearms, 500,000 methamphitamine tablets and other drugs during the same period.

Pol Lt-Gen Charnthep Sesavech, commissioner of First Region Provincial Police Bureau, said that the nationwide crime crackdown was meant to weed out illegal elements to ensure public safety during the Songkran festival.

He said he had instructed his men to ensure public safety at venues where there are celebrations and other entertainment activities during Songkran festival and, at the same time, urge revelers to comply with the law when travelling or while celebrating.

Source: Thai Public Broadcasting Service (Thai PBS)